Business
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
ATLANTA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women
About this update from Femasys Inc.
[{"type":"text","content":"ATLANTA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that Kathy Lee-Sepsick, Founder, President, and CEO, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference. The fireside chat will be hosted by Emily Bodnar, Life Sciences Analyst. The conference is being held on September 9 – 11, 2024 at the Lotte New York Palace Hotel. Presentation Date:September 9, 2024 Time:Available on-demand starting at 7:00 AM ET Webcast Link: https://journey.ct.events/view/40d58b25-f692-4267-996d-eb0cf50146ec A webcast of the presentation can be accessed on the investor relations section of the Femasys website. A replay of the webcast will be archived and available following the event for approximately 90 days. https://ir.femasys.com/events-and-presentations/default.aspx Kathy Lee-Sepsick and Dov Elefant, Chief Financial Officer, will be available for one-on-one meetings throughout the conference. To request a meeting and to register for the conference, click below: https://hcwevents.com/annualconference/ About Femasys Femasys is a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions, including a lead revolutionary product candidate and FDA-cleared products. FemaSeed® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is FDA-cleared and has received regulatory approval in Canada and Europe. FemBloc® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada, Europe, and other ex-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. Its diagnostic products include FemVue® and FemVue® Mini for fallopian tube ...